A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

CSPC Pharmaceutical Group

Status and phase: Not yet enrolling; Phase 3

Conditions: Hypertensive Emergency

Treatments: Drug: Clevidipine Butyrate Injectable Emulsion; Drug: Cleviprex®

Study type: Interventional

Funder types: Industry

Identifiers

NCT05783557

HC1902-002

Details and patient eligibility

About

A randomized, double-blind, active-compared phase Ш clinical trial to evaluate clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency.

Full description

This is a multicenter, randomized, double-blind, active-compared Phase III clinical study to evaluate the efficacy and safety of clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency. The Cleviprex® will be chosen as the positive controlled medicine with the same usage of the test drug.

Enrollment: 398 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years-old and ≤75 years-old, regardless of gender;
2. Patients with hypertensive emergency and sub-emergency requiring a rapid intravenous blood-pressure control: patients with SBP > 180 mmHg and/or DBP > 120 mmHg (requiring twice consecutive blood pressure measurements, 10 to 15 min apart), with or without target organ damage;
3. A potentially fertile patient is willing and required to use reliable contraceptive methods throughout the study period and for at least 3 months after initiation of test drug to avoid pregnancy in the female patient or in the male patient's partner;
4. Able to understand informed consent, participate in the experiment voluntarily and sign informed consent.

Exclusion criteria

1. Antihypertensive drugs have been used within 2 hours before the administration of test drugs;
2. Patients with life-threatening clinical manifestations, such as malignant arrhythmias, respiratory failure, and severe disturbance of consciousness;
3. Patients with confirmed or suspected severe aortic stenosis or aortic dissection at screening time;
4. Patients with obstructive hypertrophic cardiomyopathy and systolic heart failure at screening time;
5. Patients with acute coronary syndrome at screening or myocardial infarction within 1 month before screening;
6. Patients with acute stroke within 1 month before screening;
7. Patients with clear history of secondary hypertension;
8. Patients with lipid metabolism defects;
9. Patients with a known history of liver failure or cirrhosis;
10. Patients with chronic kidney disease (CKD) stage 5, requiring long-term regular dialysis treatment;
11. Patients who are allergic to the test drug or its ingredients, or who are intolerant to calcium channel blockers, or who are allergic to soy, soy products, eggs and egg products;
12. Patients with mental illness, mental disorder and other disorders who cannot communicate properly;
13. A history of drug abuse, drug use, or alcohol dependence;
14. Female patients who are pregnant or lactating;
15. Patients who have participated in other interventional clinical trials within 3 months prior to screening;
16. Patients who are judged by the investigators to be ineligible for this study for other factors, such as patients who could not receive intravenous infusion.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

398 participants in 2 patient groups

Experimental Group

Experimental group

Description:

Experimental Group

Treatment:

Drug: Clevidipine Butyrate Injectable Emulsion

Active-compared Group

Active Comparator group

Description:

Active-compared Group

Treatment:

Drug: Cleviprex®